CA-JSR-LIFE-SCIENCES
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis .
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Releases 2025 Sustainability Materiality Report12.9.2025 11:00:00 CEST | Press release
Insights will inform PMI’s sustainability strategy for 2030+ and help to future-proof its business for enduring success Philip Morris International Inc. (NYSE: PM) today published its 2025 Sustainability Materiality Report, presenting the results of its latest global sustainability materiality assessment (SMA). Following the principles of double materiality, the report outlines the key sustainability topics identified, along with their associated impacts, risks, and opportunities (IROs), in line with the EU Corporate Sustainability Reporting Directive (CSRD). Consumers and end users remain the company’s core priority, with a focus on product health impact and ensuring responsible marketing and sales. “The insights gained through our sustainability materiality assessment are more than just data points; they are the bedrock on which our 2030+ sustainability strategy is being built,” said Jennifer Motles, Chief Sustainability Officer. “By placing sustainability at the core of our strategy
Other World Computing and Hedge Deepen Partnership with OWC Innergize Integration into Hedge OffShoot12.9.2025 08:30:00 CEST | Press release
New Offering to be Showcased During this Week’s IBC2025, in OWC’s Booth: Hall 7, Booth 7.A60 Other World Computing (OWC®), a trusted leader in high-performance storage, memory, connectivity, software, and accessories that empower creative and business professionals to maximize performance, enhance reliability, and streamline workflows, today announced an expanded partnership with Hedge. OWC’s Innergize™ software is now integrated into Hedge’s flagship media management and backup application, OffShoot, delivering creative professionals faster, safer, and more reliable workflows. OffShoot is widely recognized as the industry standard for media offloading and backup. Built for macOS, it enables users to create multiple verified copies and archives from cards, drives, and other media simultaneously, with checksum verification to ensure absolute data integrity. With this integration, OffShoot users can now also take advantage of OWC Innergize’s unique ability to monitor card health, perform
Kawasaki Heavy Industries and Amber Kinetics Launch New Technology System Modernizing Power Grids12.9.2025 07:22:00 CEST | Press release
On May 20, 2025, following successful product demonstrations, Kawasaki Heavy Industries, Ltd. (KHI) and Amber Kinetics (AK) signed an MOU extending their collaboration to promote KHI’s iVSG (Virtual Synchronous Generator) technology with AK’s FESS (Flywheel Energy Storage System). This partnership aims to provide reliability, stability and resiliency to power grids. As renewable energy sources integrate further with power grids, the more unstable it becomes, such as in the major blackout that recently happened in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827017082/en/ Naoki Murakami, Executive Officer of KHI (left) and Edgar Chua, Chief Executive Officer of AK (right) sign MOU extension in Manila, Philippines KHI highly evaluated AK’s FESS over chemical batteries due to its superior features like unlimited cycling, no fire or explosion risk, and no environmental disposal issues, as well as AK’s
Via Announces Pricing of Initial Public Offering12.9.2025 05:34:00 CEST | Press release
Via Transportation, Inc. (“Via”), a leading provider of technology to power public transit networks, today announced the pricing of its initial public offering of 10,714,285 shares of its Class A common stock at a public offering price of $46.00 per share. Via is offering 7,142,857 shares of Class A common stock and the selling stockholders are offering 3,571,428 shares of Class A common stock. In addition, Via has granted the underwriters a 30-day option to purchase up to an additional 1,607,142 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares of Class A common stock are expected to begin trading on the New York Stock Exchange on September 12, 2025 under the ticker symbol “VIA.” The closing of the offering is expected to occur on September 15, 2025, subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC, Morgan Stanley, Allen & Company LLC, and Wells Fargo Securities are acting as
Mirion to Join the U.S. Industry Program at the 69th IAEA General Conference in Vienna, Austria11.9.2025 22:39:00 CEST | Press release
Company leaders to attend premier international meeting of nuclear officials as a U.S. Industry Delegate, showcasing Mirion impact and leadership in nuclear safety and innovation Mirion, a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, is honored to announce its invitation to attend the 69th International Atomic Energy Agency (IAEA) General Conference. Scheduled for September 15–19 in Vienna, Austria, this annual event brings together key stakeholders from across the globe to discuss issues critical to nuclear safety, security, and peaceful applications of nuclear technology. Representing Mirion at the General Conference will be Chairman and Chief Executive Officer Thomas Logan and Chief Financial Officer Brian Schopfer. Their presence underscores the distinguished role Mirion plays as an industry leader in nuclear measurement, radiation protection, and safety solutions, in addition to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom